EWTX Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About EWTX Interactive Breakdown Better Bets vs. EWTX Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Clinical Pipeline Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    Edgewise Therapeutics (EWTX)

    Market Price (10/11/2026): $39.045 | Market Cap: $4.2 BilSector: Health Care | Industry: Biotechnology

    Edgewise Therapeutics (EWTX)

    Market Price (10/11/2026): $39.045
    Market Cap: $4.2 Bil
    Sector: Health Care
    Industry: Biotechnology

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11%

    Megatrend and thematic drivers
    Megatrends include Precision Medicine. Themes include Targeted Therapies, Biopharmaceutical R&D, and Rare Disease Therapies.

    Meaningful short interest
    Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 10%

    Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

    Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -219 Mil

    Stock price has recently run up significantly
    12M Rtn12 month market price return is 159%

    Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10%

    Key risks
    EWTX key risks include [1] its heavy dependence on successful clinical trial outcomes for its lead drug candidates, Show more.

    0 Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -11%
    1 Megatrend and thematic drivers
    Megatrends include Precision Medicine. Themes include Targeted Therapies, Biopharmaceutical R&D, and Rare Disease Therapies.
    2 Meaningful short interest
    Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 10%
    3 Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
    4 Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -219 Mil
    5 Stock price has recently run up significantly
    12M Rtn12 month market price return is 159%
    6 Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10%
    7 Key risks
    EWTX key risks include [1] its heavy dependence on successful clinical trial outcomes for its lead drug candidates, Show more.

    EWTX in ETFs

    Weight = EWTX's share of each fund

    VTI0.01%
    ITOT0.00%
    IWM0.09%
    IBB0.24%
    IWO0.19%
    VTWO0.09%
    SCHA0.08%
    ESML0.05%
    +6 more covered ETFs

    Valuation & Metrics

    FYE: 12/31EWTX [1]S&P 500 [2]
    REVENUE GROWTH
    LTM Revenue [3]$0.0 Mil—
    FY 2026 Sales$2.3 Mil—
    FY 2027 Sales$38.6 Mil—
    FY 2026 Sales Growth——
    FY 2027 Sales Growth1,600.4%13.1%
    EARNINGS
    LTM Net Income (GAAP) [3]$-197.2 Mil—
    FY 2026 Net Income (Non-GAAP)$-214.4 Mil—
    FY 2027 Net Income (Non-GAAP)$-197.5 Mil—
    FY 2027 Net Income Growth—18.9%
    FY 2026 EPS (Non-GAAP)$-2.05—
    FY 2027 EPS (Non-GAAP)$-1.64—
    FY 2027 EPS Growth——
    VALUATION
    FY 2026 P/S1,849.71.7
    FY 2027 P/S108.8—
    FY 2026 P/E—7.9
    FY 2027 P/E——

    [1] EWTX forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
    [2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 10/31/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
    [3] LTM = reported trailing-twelve-month actuals (GAAP).
    null

    AI Analysis | Feedback

    MetricValueDateSource
    GRAND CANYON Trial Enrollment1752282025Link
    MESA Open-Label Extension Trial Enrollment Rate99% of eligible participants9302025Link
    Sevasemten Clinical Trial Phase (Becker and Duchenne Muscular Dystrophies)Late-stage clinical trials1162025Link
    EDG-7500 Clinical Trial Phase (Hypertrophic Cardiomyopathy)Phase 21172025Link
    EDG-15400 Clinical Trial Phase (Heart Failure)Phase 11172025Link

    Price Chart

    null
    Upcoming
    11/05/2026Earnings ReleaseRev: $129 Mil (E)
    EPS: $-0.53 (E)

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 10/1/2026

    Edgewise Therapeutics (EWTX) stock has lost about 5% since 6/30/2026 because of the following key factors:

    1. Fiscal Q2 2026 Earnings Miss: Edgewise Therapeutics reported its fiscal Q2 2026 earnings (for the period ending June 30, 2026) on August 5, 2026, posting an Earnings Per Share (EPS) of -$0.53. This result missed analysts' expectations of -$0.48 by 10.42%. This wider-than-anticipated loss likely tempered investor sentiment and contributed to the stock's tendency to remain range-bound during the specified period.

    2. Strategic Portfolio Restructuring and Bolstered Balance Sheet: On July 13, 2026, Edgewise Therapeutics completed the sale of its muscular dystrophy business, including the sevasemten program, for up to $2.65 billion. This strategic divestment significantly strengthened the company's balance sheet, with cash, cash equivalents, and marketable securities reported at approximately $460.7 million as of June 30, 2026. While enhancing long-term financial stability and focusing the pipeline on cardiovascular diseases, this major portfolio shift also led to a period of market re-evaluation, contributing to the stock's consolidation as investors assessed the implications of the new strategic direction.

    Show more
    Updated on 10/1/2026

    Edgewise Therapeutics (EWTX) stock has lost about 5% since 6/30/2026 because of the following key factors:

    1. Fiscal Q2 2026 Earnings Miss: Edgewise Therapeutics reported its fiscal Q2 2026 earnings (for the period ending June 30, 2026) on August 5, 2026, posting an Earnings Per Share (EPS) of -$0.53. This result missed analysts' expectations of -$0.48 by 10.42%. This wider-than-anticipated loss likely tempered investor sentiment and contributed to the stock's tendency to remain range-bound during the specified period.

    2. Strategic Portfolio Restructuring and Bolstered Balance Sheet: On July 13, 2026, Edgewise Therapeutics completed the sale of its muscular dystrophy business, including the sevasemten program, for up to $2.65 billion. This strategic divestment significantly strengthened the company's balance sheet, with cash, cash equivalents, and marketable securities reported at approximately $460.7 million as of June 30, 2026. While enhancing long-term financial stability and focusing the pipeline on cardiovascular diseases, this major portfolio shift also led to a period of market re-evaluation, contributing to the stock's consolidation as investors assessed the implications of the new strategic direction.

    3. Positive EDG-7500 Clinical Data Followed by Market Consolidation: The company announced positive top-line data from its 12-week Phase 2 CIRRUS-HCM trial for EDG-7500, a cardiac sarcomere modulator for hypertrophic cardiomyopathy (HCM). This favorable clinical news likely spurred the stock to reach a 52-week high of $48.51 on September 16, 2026. However, following this peak, the stock price subsequently consolidated, settling back towards its pre-surge levels by early October 2026, indicating that while the data provided a temporary catalyst, investors either realized profits or awaited further developments for sustained upward momentum.

    4. Consistent but Not Highly Bullish Analyst Ratings: Throughout the period, Edgewise Therapeutics maintained a consensus "Moderate Buy" or "Buy" rating from analysts. The average price target ranged from approximately $50.89 to $52.62, representing a modest upside from its trading levels. For example, on October 4, 2026, Wall Street Zen upgraded the stock from a "Sell" to a "Hold" rating. This generally stable but not overwhelmingly bullish analyst sentiment, coupled with relatively moderate price targets, contributed to the stock's tendency to trade within a defined range.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    The -3.9% change in EWTX stock from 6/30/2026 to 10/10/2026 was primarily driven by a -0.5% change in the company's Shares Outstanding (Mil).
    (LTM values as of)630202610102026Change
    Stock Price ($)40.6339.06-3.9%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)107108-0.5%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    6/30/2026 to 10/10/2026
    ReturnCorrelation
    EWTX-3.9% 
    Market (SPY)4.3%24.2%
    Sector (XLV)7.7%9.0%

    Fundamental Drivers

    The 24.0% change in EWTX stock from 3/31/2026 to 10/10/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
    (LTM values as of)331202610102026Change
    Stock Price ($)31.5039.0624.0%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)106108-1.5%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    3/31/2026 to 10/10/2026
    ReturnCorrelation
    EWTX24.0% 
    Market (SPY)20.0%25.0%
    Sector (XLV)17.0%8.1%

    Fundamental Drivers

    The 140.8% change in EWTX stock from 9/30/2025 to 10/10/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
    (LTM values as of)930202510102026Change
    Stock Price ($)16.2239.06140.8%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)105108-2.5%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    9/30/2025 to 10/10/2026
    ReturnCorrelation
    EWTX140.8% 
    Market (SPY)17.8%22.6%
    Sector (XLV)24.3%14.7%

    Fundamental Drivers

    The 581.7% change in EWTX stock from 9/30/2023 to 10/10/2026 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).
    (LTM values as of)930202310102026Change
    Stock Price ($)5.7339.06581.7%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)63108-41.1%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    9/30/2023 to 10/10/2026
    ReturnCorrelation
    EWTX581.7% 
    Market (SPY)88.4%27.2%
    Sector (XLV)38.9%21.8%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    EWTX Return-49%-41%22%144%-7%58%31%
    Peers Return-11%-4%88%50%53%-28%167%
    S&P 500 Return27%-19%24%23%16%13%107%

    Monthly Win Rates [3]
    EWTX Win Rate40%25%42%50%50%60% 
    Peers Win Rate43%55%48%52%55%40% 
    S&P 500 Win Rate75%42%67%75%67%50% 

    Max Drawdowns [4]
    EWTX Max Drawdown--70%-51%-31%-62%-21% 
    Peers Max Drawdown-55%-52%-53%-47%-51%-46% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: CYTK, SRPT, BBIO, DYN, RNA.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 10/9/2026 (YTD)

    How Low Can It Go

    EventEWTXS&P 500
    2025 US Tariff Shock
      % Loss-57.2%-18.8%
      % Gain to Breakeven133.5%23.1%
      Time to Breakeven257 days79 days
    2024 Yen Carry Trade Unwind
      % Loss-26.2%-7.8%
      % Gain to Breakeven35.5%8.5%
      Time to Breakeven43 days18 days
    Summer-Fall 2023 Five Percent Yield Shock
      % Loss-21.2%-9.5%
      % Gain to Breakeven26.9%10.5%
      Time to Breakeven33 days24 days
    2023 SVB Regional Banking Crisis
      % Loss-42.9%-6.7%
      % Gain to Breakeven75.1%7.1%
      Time to Breakeven43 days31 days
    2022 Inflation Shock & Fed Tightening
      % Loss-65.7%-24.5%
      % Gain to Breakeven191.4%32.4%
      Time to Breakeven611 days427 days

    Compare to CYTK, SRPT, BBIO, DYN, RNA

    In The Past

    Edgewise Therapeutics's stock fell -57.2% during the 2025 US Tariff Shock. Such a loss loss requires a 133.5% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    EventEWTXS&P 500
    2025 US Tariff Shock
      % Loss-57.2%-18.8%
      % Gain to Breakeven133.5%23.1%
      Time to Breakeven257 days79 days
    2024 Yen Carry Trade Unwind
      % Loss-26.2%-7.8%
      % Gain to Breakeven35.5%8.5%
      Time to Breakeven43 days18 days
    Summer-Fall 2023 Five Percent Yield Shock
      % Loss-21.2%-9.5%
      % Gain to Breakeven26.9%10.5%
      Time to Breakeven33 days24 days
    2023 SVB Regional Banking Crisis
      % Loss-42.9%-6.7%
      % Gain to Breakeven75.1%7.1%
      Time to Breakeven43 days31 days
    2022 Inflation Shock & Fed Tightening
      % Loss-65.7%-24.5%
      % Gain to Breakeven191.4%32.4%
      Time to Breakeven611 days427 days

    Compare to CYTK, SRPT, BBIO, DYN, RNA

    In The Past

    Edgewise Therapeutics's stock fell -57.2% during the 2025 US Tariff Shock. Such a loss loss requires a 133.5% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About Edgewise Therapeutics (EWTX)

    ```html

    Edgewise Therapeutics, Inc. (EWTX) is a biopharmaceutical company dedicated to developing innovative small molecule therapies for musculoskeletal diseases. The company's focus is on creating treatments that address the root causes of these conditions, rather than just managing symptoms, particularly for genetically defined muscle disorders.

    The company's lead product candidate is EDG-5506, an orally administered small molecule therapy. EDG-5506 is specifically designed to treat dystrophinopathies, which include serious muscle-wasting conditions like Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD). This therapy has successfully completed Phase 1 clinical trials, marking a significant step in its development.

    Beyond EDG-5506, Edgewise Therapeutics is actively developing a broader pipeline of precision medicine product candidates. These therapies are engineered to target key muscle proteins and modulators, aiming to serve patients suffering from a variety of other genetically defined muscle disorders. The company's primary market is individuals affected by these debilitating inherited muscle diseases.

    ```

    AI Analysis | Feedback

    Here are a few analogies for Edgewise Therapeutics (EWTX):

    • Like a Sarepta Therapeutics (SRPT), but developing small molecule treatments for muscle disorders.
    • Like a Vertex Pharmaceuticals (VRTX), but focused on small molecule therapies for muscle diseases instead of cystic fibrosis.

    AI Analysis | Feedback

    • EDG-5506: An orally administered small molecule therapy designed to address the root cause of dystrophinopathies, including Duchenne and Becker muscular dystrophy.

    AI Analysis | Feedback

    As a biopharmaceutical company focused on developing therapies for musculoskeletal diseases, Edgewise Therapeutics (EWTX) is currently in the clinical development stage. Its lead product candidate, EDG-5506, has completed Phase 1 clinical trials.

    Since the company's therapeutic products are still under development and have not yet been commercialized or approved for sale, Edgewise Therapeutics does not currently have major customers that purchase its products.

    AI Analysis | Feedback

    • Lonza Ltd. (LONN)

    AI Analysis | Feedback

    Kevin Koch, Ph.D. President and Chief Executive Officer

    Dr. Koch has served as President, Chief Executive Officer, and a member of Edgewise Therapeutics' board of directors since 2017. He brings over 30 years of experience in the life science industry, focusing on drug discovery, translational medicine, and clinical development. Since 2016, Dr. Koch has also been a Venture Partner with OrbiMed, a healthcare-focused investment firm. Previously, he was the Senior Vice President of Drug Discovery, Chemical and Molecular Therapeutics at Biogen, where he managed global drug discovery and biomarker development.

    Michael Nofi Chief Financial Officer

    Mr. Nofi was appointed Chief Financial Officer of Edgewise Therapeutics on November 10, 2025. Before joining Edgewise, he served as Chief Accounting Officer (CAO) at SpringWorks Therapeutics, Inc. Prior to his role at SpringWorks, Mr. Nofi was the CAO and Vice President of Global Accounting and Corporate FP&A at The Nature's Bounty Co. His career also includes senior finance positions at Acorda Therapeutics, Allergan plc, and Forest Laboratories.

    Alan Russell, Ph.D. Co-Founder and Chief Scientific Officer

    Dr. Russell is a co-founder of Edgewise Therapeutics and serves as its Chief Scientific Officer and a member of the board of directors.

    Joanne M. Donovan, M.D., Ph.D. Chief Medical Officer

    Dr. Donovan was appointed Chief Medical Officer of Edgewise Therapeutics in April 2021. She has extensive experience in the biotechnology industry, having previously served as Chief Medical Officer and Senior Vice President, Clinical Development at Catabasis Pharmaceuticals, where she led clinical development for Duchenne muscular dystrophy from first-in-human through Phase 3 studies. Dr. Donovan also held various positions, including Vice President of Clinical Development, at Genzyme, a company she joined through its acquisition of GelTex Pharmaceuticals. She is also a staff physician at the VA Boston Healthcare System and an Associate Clinical Professor of Medicine at Harvard Medical School.

    Behrad Derakhshan, Ph.D. Chief Operating Officer

    Dr. Derakhshan was promoted to Chief Operating Officer in January 2025, having previously served as Chief Business Officer since joining Edgewise in 2020. In his roles, he has been responsible for strategic planning, business development, capital formation, investor relations, corporate communications, and commercial planning. Dr. Derakhshan played a key role in the company's initial public offering and in securing several additional funding rounds.

    AI Analysis | Feedback

    The key risks for Edgewise Therapeutics (EWTX) are primarily associated with the inherent challenges of developing and commercializing biopharmaceutical products, particularly for a clinical-stage company with no approved products on the market.

    1. Clinical Trial and Regulatory Approval Risk: As a biopharmaceutical company, Edgewise Therapeutics' success is heavily dependent on the successful development, clinical trials, and regulatory approval of its product candidates, especially sevasemten (formerly EDG-5506) for muscular dystrophies and EDG-7500 for hypertrophic cardiomyopathy. The clinical development process is lengthy, expensive, and its outcome is uncertain. There is no assurance that clinical trials will demonstrate the necessary safety and efficacy to satisfy regulatory authorities like the FDA or EMA, or that they will produce positive results. For example, while promising long-term results have been reported for sevasemten in Becker muscular dystrophy, top-line results from the pivotal GRAND CANYON study are still pending in Q4 2026. Failures at any stage of clinical development, including unexpected adverse events such as the atrial fibrillation risk noted for EDG-7500, could delay or prevent regulatory approval and commercialization, substantially harming the business.
    2. Financial Risk and Lack of Approved Products: Edgewise Therapeutics is an early-stage company without any approved products for commercial sale, meaning it currently generates no revenue. The company has a limited operating history and incurs significant net losses, primarily due to high research and development expenses, such as the full-year 2025 net loss of $167.8 million. This financial profile complicates the evaluation of its business viability. The company is continuously burning cash and relies on securing additional capital through equity or debt offerings to fund its ongoing operations, clinical advancements, and future commercialization activities. Fluctuations in the availability of capital due to macroeconomic events could impact its ability to raise necessary funds.
    3. Dependence on Third Parties for Clinical Trials and Manufacturing: Edgewise Therapeutics relies on third parties for conducting its clinical trials and for manufacturing its product candidates. There is an operational risk that these third parties may not perform satisfactorily, which could lead to delays in development or commercialization efforts. Any issues with the production of drugs by third-party manufacturers or changes in manufacturing methods or formulations could also pose significant challenges.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Edgewise Therapeutics' lead product candidate, EDG-5506, targets Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD).

    Duchenne Muscular Dystrophy (DMD)

    • The global Duchenne muscular dystrophy drugs market size was estimated at USD 3.47 billion in 2023 and is projected to reach USD 9.91 billion by 2030.
    • Another estimate places the global DMD drugs market at USD 2.3 billion in 2023, with an expected increase to USD 5.5 billion by 2032.
    • The Duchenne muscular dystrophy market size in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) was around USD 2,150 million in 2023.
    • The United States accounts for the largest Duchenne muscular dystrophy market size, at approximately USD 1,900 million in 2023. North America dominated the global Duchenne muscular dystrophy drugs market with a 45.0% revenue share in 2023.

    Becker Muscular Dystrophy (BMD)

    • The global Becker muscular dystrophy treatment market size was valued at USD 1.92 billion in 2024 and is expected to reach USD 2.83 billion by 2032.
    • The Becker muscular dystrophy market across the top 7 markets (US, EU4, UK, and Japan) reached a value of USD 880.6 million in 2024 and is expected to reach USD 1,355.1 million by 2035.
    • In 2024, the United States accounted for the largest Becker Muscular Dystrophy market size compared to EU4, the UK, and Japan. North America dominated the Becker muscular dystrophy treatment market with the largest revenue share of 42.8% in 2024.

    AI Analysis | Feedback

    Edgewise Therapeutics (EWTX) is a biopharmaceutical company focused on developing therapies for musculoskeletal diseases and serious cardiac conditions. The company's future revenue growth over the next 2-3 years is anticipated to be driven by the following key factors:

    1. Commercialization of Sevasemten (EDG-5506) for Becker Muscular Dystrophy: Edgewise Therapeutics expects to announce top-line data from the pivotal GRAND CANYON study for sevasemten in Becker muscular dystrophy in the fourth quarter of 2026. A New Drug Application (NDA) submission for sevasemten in Becker is planned for the first half of 2027, with a potential commercial launch anticipated by the fourth quarter of 2027 and the first full year of revenue in 2028. Sevasemten has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for Becker muscular dystrophy, and analysts project significant revenue in 2027 and 2028 if commercialized successfully. The market potential for this program is estimated at $5 billion.
    2. Advancement of Sevasemten (EDG-5506) for Duchenne Muscular Dystrophy: The company has reported positive results from its Phase 2 Duchenne trials (LYNX and FOX) for sevasemten. Edgewise plans to initiate a pivotal Phase 3 study for Duchenne muscular dystrophy in 2026. EDG-5506 has already been granted Fast Track, Orphan Drug, and Rare Pediatric Disease designations by the FDA for Duchenne muscular dystrophy, which could expedite its development and review process.
    3. Progression of EDG-7500 for Hypertrophic Cardiomyopathy (HCM): Edgewise Therapeutics anticipates reporting 12-week Part D data from the Phase 2 CIRRUS-HCM study for EDG-7500 in the first half of 2026. These results are expected to inform the design and initiation of Phase 3 trials in both obstructive and nonobstructive HCM in the fourth quarter of 2026. EDG-7500 is considered a differentiated treatment with a potential market size of $10 billion.
    4. Development of EDG-15400 for Heart Failure with Preserved Ejection Fraction (HFpEF): The company expects to announce top-line results from its Phase 1 healthy adult trial of EDG-15400 in the first half of 2026. Following this, Edgewise plans to initiate a Phase 2 trial for EDG-15400 in participants with heart failure with preserved ejection fraction (HFpEF) in the second half of 2026.

    AI Analysis | Feedback

    Capital Allocation Decisions for Edgewise Therapeutics (EWTX)

    Share Issuance

    • Edgewise Therapeutics secured $240 million in funding in November 2024, representing a significant share issuance.
    • The number of outstanding shares increased by 11.38% in the year leading up to early 2026.
    • The company became public through an Initial Public Offering (IPO) in 2021.

    Inbound Investments

    • Edgewise Therapeutics received $240 million in funding in November 2024, intended to advance its pipeline of novel treatments and clinical trials for muscle diseases.

    Capital Expenditures

    • Capital expenditures totaled approximately $256,000 over the 12 months ending in early 2026.
    • The company reported capital expenditures of $73,000 in the fourth quarter of 2025.
    • Capital is primarily focused on supporting ongoing clinical trials and near-term development plans for its muscular dystrophy and cardiovascular programs.

    Peer Outperformance in Biotechnology

    EWTX has outperformed 89% of its 363 Biotechnology peers over 5Y. Biotechnology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
    Share of Biotechnology constituents that EWTX has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    93%
    of 454 industry peers · 158.5% return
    3Y
    92%
    of 401 industry peers · 470.2% return
    5Y
    89%
    of 363 industry peers · 129.8% return
    No Biotechnology peer with a comparable growth profile has beaten EWTX by more than 20pp over 5Y.
    Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is EWTX's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Health Care Distributors 6 13.0%45.5%92.4% CAH 440% · MCK 377% · COR 179%
    Health Care Services 20 22.6%34.2%13.0% HIMS 313% · RDNT 161% · DGX 81%
    Managed Health Care 8 37.5%-6.1%6.4% OSCR 136% · HQY 43% · ELV 17%
    Health Care Facilities 24 1.7%8.7%5.4% THC 325% · NHC 277% · ENSG 143%
    Health Care Equipment 50 -2.8%0.5%-15.7% POCI 11350% · UFPT 359% · GKOS 271%
    Pharmaceuticals 62 -7.3%-3.2%-29.4% INDV 1102% · ETON 1009% · LQDA 792%
    Health Care Supplies 12 30.5%-8.0%-35.0% LNTH 332% · HAE 78% · MMSI 22%
    Life Sciences Tools & Services 109 -8.6%-10.1%-63.2% SNWV 2194% · NTRA 259% · MEDP 232%
    Biotechnology ← 364 -17.4%-25.3%-79.7% DNTH 1102% · CELZ 1098% · ELVN 953%
    Health Care Technology 21 -27.9%-59.5%-82.0% SPOK 78% · HSTM 19% · VEEV 4%
    Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

    Latest Trefis Analyses

    Recent Active Movers

    Top Gainers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    PCRXPacira BioSciences1.444.0%40.3%
    OPCHOption Care Health4.837.2%-2.5%
    PTCPTC22.335.0%11.6%
    PRMEPrime Medicine0.733.9%15.0%
    PCVXVaxcyte10.326.4%54.7%
    QDELQuidelOrtho0.924.6%-53.0%
    RXORXO4.924.4%130.1%
    PENGPenguin Solutions3.924.3%290.0%
    NVAXNovavax2.121.9%89.7%
    HPKHighPeak Energy1.221.7%101.5%

    Top Losers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    AVBPArriVent BioPharma0.8-40.8%-16.8%
    ALMRAlamar Biosciences1.5-26.5%14.9%
    NUAINew Era Energy & Digital0.5-25.4%60.2%
    SHAZSharonAI0.7-25.3%-59.0%
    ANGOAngioDynamics0.5-23.8%-10.3%
    GLASGlass House Brands0.4-22.4%-51.9%
    EOSEEos Energy Enterprises0.9-21.5%-78.0%
    AEHRAehr Test Systems2.7-21.1%319.2%
    YSSYork Space Systems0.9-20.8%-78.8%
    AXTIAXT4.2-20.3%318.7%

    Top Gainers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    MYPSPLAYSTUDIOS0.5740.5%530.4%
    KODKodiak Sciences6.3203.8%257.2%
    DNAGinkgo Bioworks0.891.7%56.4%
    PACBPacific Biosciences of California0.783.5%24.6%
    GRALGRAIL6.181.3%64.2%
    IOVAIovance Biotherapeutics6.679.6%435.5%
    SECZSecuritize2.071.9%12.4%
    MRNAModerna89.564.7%663.0%
    PEverpure51.464.2%130.7%
    PENGPenguin Solutions3.956.9%290.0%

    Top Losers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    CTVACorteva8.9-84.3%-80.1%
    LQDALiquidia2.4-59.6%-20.6%
    XNDUXanadu Quantum Technologies1.2-56.6%-66.1%
    QUREuniQure1.5-49.2%-5.6%
    EMATEvolution Metals & Technologies1.0-46.8%-92.3%
    GLASGlass House Brands0.4-46.6%-51.9%
    NKTRNektar Therapeutics1.4-41.7%-2.6%
    AVBPArriVent BioPharma0.8-41.7%-16.8%
    ALHCAlignment Healthcare1.6-40.9%-61.8%
    ABRArbor Realty Trust0.5-40.3%-59.2%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    EWTXCYTKSRPTBBIODYNRNAMedian
    NameEdgewise.Cytokine.Sarepta .BridgeBi.Dyne The.Atrium T. 
    Mkt Price39.0562.9217.8665.9916.638.4328.45
    Mkt Cap4.28.31.912.92.80.13.5
    Rev LTM0681,97471303652
    Op Inc LTM-219-708-62-478-537-96-348
    FCF LTM-159-58175-438-499-57-298
    FCF 3Y Avg-130-473-302-508-360--360
    CFO LTM-158-555111-434-478-53-296
    CFO 3Y Avg-129-460-195-502-352--352

    Growth & Margins

    EWTXCYTKSRPTBBIODYNRNAMedian
    NameEdgewise.Cytokine.Sarepta .BridgeBi.Dyne The.Atrium T. 
    Rev Chg LTM--21.1%-20.4%202.4%---20.4%
    Rev Chg 3Y Avg-848.7%31.5%1,323.7%--848.7%
    Rev Chg Q--57.1%-34.3%120.4%--21.9%-28.1%
    QoQ Delta Rev Chg LTM--36.0%-9.6%23.0%--2.3%-6.0%
    Op Inc Chg LTM-25.4%-29.4%-6,578.0%26.0%-21.8%--25.4%
    Op Inc Chg 3Y Avg-34.2%-14.2%-2,191.0%-0.3%-41.2%--34.2%
    Op Mgn LTM--1,046.1%-3.2%-67.0%--269.0%-168.0%
    Op Mgn 3Y Avg--5,944.2%-0.2%-190.1%---190.1%
    QoQ Delta Op Mgn LTM--441.1%-3.2%19.9%--32.8%-18.0%
    CFO/Rev LTM--820.8%5.6%-60.9%--148.4%-104.7%
    CFO/Rev 3Y Avg--4,684.0%-10.9%-176.1%---176.1%
    FCF/Rev LTM--858.2%3.8%-61.4%--157.7%-109.5%
    FCF/Rev 3Y Avg--4,704.2%-16.5%-178.7%---178.7%

    Valuation

    EWTXCYTKSRPTBBIODYNRNAMedian
    NameEdgewise.Cytokine.Sarepta .BridgeBi.Dyne The.Atrium T. 
    Mkt Cap4.28.31.912.92.80.13.5
    P/S-122.81.018.1-4.011.1
    P/Op Inc-19.2-11.7-30.2-27.0-5.1-1.5-15.5
    P/EBIT-19.2-10.8-31.8-26.0-5.5-1.5-15.0
    P/E-21.3-9.3-13.8-18.7-5.3-1.5-11.5
    P/CFO-26.5-15.017.0-29.7-5.8-2.7-10.4
    Total Yield-4.7%-10.8%-7.3%-5.4%-18.9%-64.8%-9.0%
    Dividend Yield0.0%0.0%0.0%0.0%0.0%0.0%0.0%
    FCF Yield 3Y Avg-5.1%-6.8%-8.9%-6.3%-16.8%--6.8%
    D/E0.00.20.60.20.10.00.1
    Net D/E-0.10.00.10.1-0.2-1.8-0.0

    Returns

    EWTXCYTKSRPTBBIODYNRNAMedian
    NameEdgewise.Cytokine.Sarepta .BridgeBi.Dyne The.Atrium T. 
    1M Rtn-9.0%-14.5%-13.0%-9.0%-9.7%-18.6%-11.4%
    3M Rtn-14.0%-25.9%-5.8%-23.2%-29.0%-32.3%-24.5%
    6M Rtn19.0%-3.2%-15.7%-11.5%-11.0%-33.7%-11.3%
    12M Rtn158.4%4.8%-19.2%18.9%18.4%-83.1%11.6%
    3Y Rtn470.0%75.0%-85.7%147.6%98.4%30.1%86.7%
    1M Excs Rtn-11.9%-17.4%-15.9%-11.9%-12.6%-21.5%-14.2%
    3M Excs Rtn-9.3%-27.4%-9.1%-24.6%-33.6%-35.0%-26.0%
    6M Excs Rtn4.4%-17.8%-30.3%-26.3%-25.6%-48.3%-25.9%
    12M Excs Rtn138.7%-12.2%-39.3%3.5%-1.4%-98.3%-6.8%
    3Y Excs Rtn466.5%49.4%-168.1%90.7%17.0%-36.4%33.2%

    Comparison Analyses

    null

    Financials

    $ Mil | FY: 12/312026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q3
    Period End6/30/20263/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/2023
    Filing Date8/6/20265/7/20262/26/202611/6/20258/7/20255/8/20253/3/202511/7/20248/8/20245/9/20242/22/202411/9/2023
    Key Financials Quarterly            
    Total Revenue000000000000
    Ebitda-61-54-55-46-42-45-45-40-38-34-33-29
    Operating Income-62-54-56-47-43-46-46-40-38-35-34-29
    Net Income-57-49-50-41-36-41-40-34-31-29-30-26
    EPS-0.53-0.46-0.47-0.39-0.34-0.43-0.42-0.36-0.34-0.33-0.47-0.41
    Key Financials TTM            
    Total Revenue TTM000000000000
    Ebitda TTM-217-197-189-179-172-168-157-145-134-121-113-101
    Operating Income TTM-219-200-191-181-175-170-159-147-136-123-114-103
    Net Income TTM-197-176-168-157-151-146-134-124-116-106-100-89
    Growth Rates Quarterly            
    Total Revenue Growth------------
    EBITDA Growth-45.9%-17.9%-23.4%-16.2%-11.9%-32.7%-34.8%-37.6%-51.0%-34.4%-51.6%-60.0%
    Operating Income Growth-45.4%-17.7%-22.9%-15.9%-11.8%-32.2%-34.5%-37.3%-50.4%-35.2%-53.4%-61.3%
    Net Income Growth-58.7%-20.1%-26.6%-19.2%-14.7%-43.0%-31.6%-32.7%-46.7%-24.9%-55.3%-46.9%
    Margins Quarterly            
    EBITDA Margin------------
    Operating Income Margin------------
    Net Income Margin------------
    Cash & Debt            
    Total Cash461500530563594436470493512533318290
    Total Debt444445545556
    Net Debt / (Cash)-457-496-526-559-590-432-465-488-507-528-313-284
    Cash Flows Quarterly            
    FCF from Operations-42-43-39-35-33-38-27-27-26-29-27-22
    Cash Flows TTM            
    FCF from Operations TTM-158-148-144-132-125-118-109-109-104-98-92-77
    Returns to Shareholders Quarterly            
    Dividends000000000000
    Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
    Return on Invested Capital (ROIC) Quarterly            
    ROIC-38.5%-36.5%-41.3%-37.8%-37.5%-44.1%-48.9%-47.6%-49.4%-49.5%-54.0%-53.3%
    Return on Invested Capital (ROIC) TTM            
    ROIC TTM-34.0%-33.7%-35.3%-36.5%-38.4%-40.8%-42.7%-43.3%-44.1%-44.0%-45.6%-46.4%

    Segment Financials

    Operating Income by Segment
    $ Mil202520242023
    Discovery, development, and manufacture of drug products for the treatment of various muscular-191-159-114
    Total-191-159-114


    Net Income by Segment
    $ Mil202520242023
    Discovery, development, and manufacture of drug products for the treatment of various muscular-168-134-100
    Total-168-134-100


    Assets by Segment
    $ Mil20242023202220212020
    Discovery, development, and manufacture of drug products for the treatment of various muscular487340367285131
    Total487340367285131


    Price Behavior

    Price Behavior
    Market Price$39.06 
    Market Cap ($ Bil)4.2 
    First Trading Date03/26/2021 
    Distance from 52W High-19.2% 
       50 Days200 Days
    DMA Price$42.77$35.13
    DMA Trendupup
    Distance from DMA-8.7%11.2%
     3M1YR
    Volatility55.8%74.8%
    Downside Capture187.1659.07
    Upside Capture77.59156.15
    Correlation (SPY)27.9%23.3%
    EWTX Betas & Captures as of 9/30/2026

     1M2M3M6M1Y3Y
    Beta0.452.141.461.381.321.46
    Up Beta1.784.183.471.892.111.43
    Down Beta1.153.470.830.691.171.60
    Up Capture-1%141%86%153%201%530%
    Bmk +ve Days6162766132424
    Stock +ve Days10193157120377
    Down Capture80%110%99%123%61%103%
    Bmk -ve Days16263760120328
    Stock -ve Days12233369132372

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with EWTX
    EWTX155.4%74.9%1.55-
    Sector ETF (XLV)19.8%15.8%0.9415.9%
    Equity (SPY)16.7%13.0%0.9122.9%
    Gold (GLD)3.3%29.5%0.1111.5%
    Commodities (DBC)45.0%20.9%1.67-2.0%
    Real Estate (VNQ)4.8%13.8%0.098.8%
    Bitcoin (BTCUSD)-33.2%44.2%-0.797.1%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with EWTX
    EWTX18.1%80.5%0.55-
    Sector ETF (XLV)7.7%15.2%0.3124.1%
    Equity (SPY)13.9%17.1%0.6229.5%
    Gold (GLD)18.5%18.9%0.795.3%
    Commodities (DBC)10.0%19.5%0.391.2%
    Real Estate (VNQ)1.3%18.8%-0.0421.2%
    Bitcoin (BTCUSD)11.4%52.0%0.3910.3%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with EWTX
    EWTX3.0%80.1%0.41-
    Sector ETF (XLV)11.0%16.7%0.5323.0%
    Equity (SPY)15.5%17.9%0.7328.1%
    Gold (GLD)11.8%16.4%0.595.5%
    Commodities (DBC)8.2%18.1%0.371.5%
    Real Estate (VNQ)4.5%20.7%0.1819.8%
    Bitcoin (BTCUSD)63.5%66.2%1.038.2%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date9302026
    Short Interest: Shares Quantity11.2 Mil
    Short Interest: % Change Since 915202617.6%
    Average Daily Volume2.0 Mil
    Days-to-Cover Short Interest5.6 days
    Basic Shares Quantity107.7 Mil
    Short % of Basic Shares10.4%

    Earnings Returns History

    Updated 9/9/2026
    Expand for More
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/6/2026-1.3%-3.2%-6.8%
    5/7/2026-3.8%-8.7%-3.8%
    2/26/2026-1.5%-4.1%5.1%
    11/6/2025-1.6%21.9%35.6%
    8/7/2025-4.2%1.6%15.2%
    5/8/20251.2%0.2%5.0%
    3/3/2025-2.4%7.0%-15.9%
    11/7/2024-3.2%-9.2%-11.0%
    ...
    SUMMARY STATS   
    # Positive7128
    # Negative151014
    Median Positive4.6%6.7%11.6%
    Median Negative-2.4%-5.6%-7.5%
    Max Positive10.3%21.9%35.6%
    Max Negative-7.3%-15.4%-31.2%
     Collapse to Preview
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/6/2026-1.3%-3.2%-6.8%
    5/7/2026-3.8%-8.7%-3.8%
    2/26/2026-1.5%-4.1%5.1%
    11/6/2025-1.6%21.9%35.6%
    8/7/2025-4.2%1.6%15.2%
    5/8/20251.2%0.2%5.0%
    3/3/2025-2.4%7.0%-15.9%
    11/7/2024-3.2%-9.2%-11.0%
    8/8/20242.0%7.4%10.3%
    5/9/2024-4.3%-15.4%-15.5%
    2/22/2024-0.7%-4.9%-3.5%
    11/9/2023-7.3%6.3%13.0%
    8/10/20233.9%11.4%-3.4%
    5/11/2023-4.0%-6.3%-2.8%
    2/23/2023-2.0%-2.7%-31.2%
    11/3/20226.8%0.0%-5.7%
    8/4/202210.3%13.4%14.3%
    5/11/2022-3.8%0.4%-12.2%
    2/24/20224.6%1.7%-14.6%
    11/10/2021-2.2%-0.1%-3.2%
    8/9/2021-2.2%-10.6%-8.3%
    5/13/202110.0%12.5%3.3%
    SUMMARY STATS   
    # Positive7128
    # Negative151014
    Median Positive4.6%6.7%11.6%
    Median Negative-2.4%-5.6%-7.5%
    Max Positive10.3%21.9%35.6%
    Max Negative-7.3%-15.4%-31.2%

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/06/202610-Q
    03/31/202605/07/202610-Q
    12/31/202502/26/202610-K
    09/30/202511/06/202510-Q
    06/30/202508/07/202510-Q
    03/31/202505/08/202510-Q
    12/31/202403/03/202510-K
    09/30/202411/07/202410-Q
    06/30/202408/08/202410-Q
    03/31/202405/09/202410-Q
    12/31/202302/22/202410-K
    09/30/202311/09/202310-Q
    06/30/202308/10/202310-Q
    03/31/202305/11/202310-Q
    12/31/202202/23/202310-K
    09/30/202211/03/202210-Q
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/06/202610-Q
    03/31/202605/07/202610-Q
    12/31/202502/26/202610-K
    09/30/202511/06/202510-Q
    06/30/202508/07/202510-Q
    03/31/202505/08/202510-Q
    12/31/202403/03/202510-K
    09/30/202411/07/202410-Q
    06/30/202408/08/202410-Q
    03/31/202405/09/202410-Q
    12/31/202302/22/202410-K
    09/30/202311/09/202310-Q
    06/30/202308/10/202310-Q
    03/31/202305/11/202310-Q
    12/31/202202/23/202310-K
    09/30/202211/03/202210-Q
    06/30/202208/04/202210-Q
    03/31/202205/11/202210-Q
    12/31/202102/24/202210-K
    09/30/202111/10/202110-Q
    06/30/202108/09/202110-Q
    03/31/202105/13/202110-Q
    12/31/202003/26/2021424B4

    Insider Activity

    Updated 10/2/2026
    Expand for More
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Moore, John RGeneral CounselDirectSell814202643.825,016219,823775,559Form
    2Donovan, Joanne MCMODirectSell813202643.412,919126,704374,381Form
    3Donovan, Joanne MCMODirectSell813202643.856,522286,000506,222Form
    4Russell, Alan JChief Scientific OfficerDirectSell813202643.735,901258,0421,375,964Form
    5Derakhshan, BehradChief Business OfficerDirectSell813202643.815,100223,4241,394,254Form
     Collapse to Preview
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Moore, John RGeneral CounselDirectSell814202643.825,016219,823775,559Form
    2Donovan, Joanne MCMODirectSell813202643.412,919126,704374,381Form
    3Donovan, Joanne MCMODirectSell813202643.856,522286,000506,222Form
    4Russell, Alan JChief Scientific OfficerDirectSell813202643.735,901258,0421,375,964Form
    5Derakhshan, BehradChief Business OfficerDirectSell813202643.815,100223,4241,394,254Form
    6Koch, KevinPresident and CEODirectSell813202643.6817,971785,0422,292,877Form
    7Russell, Alan JChief Scientific OfficerDirectSell701202639.41200,0007,881,402967,639Form
    8Donovan, Joanne MCMODirectSell504202638.5750,0001,928,400168,426Form
    9Donovan, Joanne MCMODirectSell504202631.295,230163,663136,657Form
    10Donovan, Joanne MCMODirectSell401202632.3128,662926,095310,088Form
    11Donovan, Joanne MCMODirectSell330202630.9816,358506,735297,294Form
    12Edris, BadreddinDirectSell121202629.44115,4713,399,466583,501Form
    13Russell, Alan JChief Scientific OfficerDirectSell1113202521.12100,0002,112,450494,313Form
    14Fox, Jonathan CDirectBuy1113202518.6410,700199,403441,706Form

    Investor Activity (13F)

    Updated Oct 11, 2026
    13F holdings as of Mar 31, 2026 (Q1 2026)

    Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.

    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Novo Holdings A/S$168.5 Mil13.7%22Hold13F
    Orbimed Advisors LLC$488.8 Mil10.7%109Hold13F
    Cormorant Asset Management, LP$102.7 Mil5.2%46Hold13F
    Paradigm Biocapital Advisors LP$232.0 Mil4.7%35ADD +12.6%13F
    MPM Bioimpact LLC$52.3 Mil4.0%41Hold13F
    First Light Asset Management, LLC$31.6 Mil2.8%35TRIM -36.3%13F
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Paradigm Biocapital Advisors LP$232.0 Mil4.7%35ADD +12.6%13F
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    First Light Asset Management, LLC$31.6 Mil2.8%35TRIM -36.3%13F
    Active ManagerValue% of PortfolioTotal PositionsQoQFiling
    Orbimed Advisors LLC$488.8 Mil10.7%109Hold13F
    Paradigm Biocapital Advisors LP$232.0 Mil4.7%35ADD +12.6%13F
    Novo Holdings A/S$168.5 Mil13.7%22Hold13F
    Cormorant Asset Management, LP$102.7 Mil5.2%46Hold13F
    MPM Bioimpact LLC$52.3 Mil4.0%41Hold13F
    First Light Asset Management, LLC$31.6 Mil2.8%35TRIM -36.3%13F

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 10/10/2026